Incyte INCY ICLUSIG — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Incyte in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Incyte’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Incyte's iclusig — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Incyte's ICLUSIG — total revenues?
- Incyte (INCY) reported ICLUSIG — total revenues of $35.46M in Q1 2026.
- How has Incyte's ICLUSIG — total revenues changed year-over-year?
- Incyte's ICLUSIG — total revenues increased by 20.0% year-over-year, from $29.54M to $35.46M.
- What is the long-term trend for Incyte's ICLUSIG — total revenues?
- Over 4 years (2021 to 2025), Incyte's ICLUSIG — total revenues has grown at a 5.2% compound annual growth rate (CAGR), from $109.4M to $134.07M.
- What does ICLUSIG — total revenues mean?
- This metric represents the total gross revenue generated from the sale of a specific pharmaceutical product, in this case, a kinase inhibitor used for oncology treatments. It reflects the market adoption, pricing power, and patient demand for this specific therapeutic asset within the company's broader oncology portfolio. This figure is critical for assessing the commercial performance and lifecycle stage of the drug independent of the company's other diversified revenue streams.